Back to top
more

Immunomedics, Inc. (IMMU)

(Real Time Quote from BATS)

$16.22 USD

16.22
1,452,206

+0.40 (2.53%)

Updated Oct 22, 2019 02:26 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | F Growth | F Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for IMMU

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Immunomedics, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Assets          
Cash & Equivalents 639 639 155 51 100
Receivables 0 0 1 1 1
Notes Receivable 0 0 0 0 0
Inventories 0 0 1 0 1
Other Current Assets 10 10 1 1 2
Total Current Assets 648 648 157 53 103
Net Property & Equipment 16 16 5 4 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 664 664 163 57 106
Liabilities & Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Notes Payable 0 0 0 0 0
Accounts Payable 32 32 31 15 12
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 12 12 91 0 0
Total Current Liabilities 44 44 122 15 12
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 20 20 98 97 97
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 201 201 2 2 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 264 264 222 114 110
Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2 2 1 1 1
Capital Surplus 1,195 1,195 463 311 305
Retained Earnings -796 -796 -522 -369 -309
Other Equity -1 -1 -1 -1 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 400 400 -59 -58 -5
Total Liabilities & Shareholder's Equity 664 664 163 57 106
Total Common Equity 400 400 -59 -58 -5
Shares Outstanding 190.40 152.00 105.90 94.60 93.10
Book Value Per Share 2.10 2.63 -0.56 -0.61 -0.05

Fiscal Year End for Immunomedics, Inc. falls in the month of December.

All items in Millions except Per Share data.

9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Assets          
Cash & Equivalents NA 433 443 NA 586
Receivables NA 0 0 NA 0
Notes Receivable NA 0 0 NA 0
Inventories NA 0 0 NA 0
Other Current Assets NA 10 6 NA 8
Total Current Assets NA 442 449 NA 594
Net Property & Equipment NA 35 35 NA 19
Investments & Advances NA 0 0 NA 0
Other Non-Current Assets NA 0 0 NA 0
Deferred Charges NA 0 0 NA 0
Intangibles NA 0 0 NA 0
Deposits & Other Assets NA 0 0 NA 0
Total Assets NA 478 485 NA 613
Liabilities & Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Notes Payable NA 0 0 NA 0
Accounts Payable NA 39 54 NA 34
Current Portion Long-Term Debt NA 0 0 NA 0
Current Portion Capital Leases NA 0 0 NA 0
Accrued Expenses NA 0 0 NA 0
Income Taxes Payable NA 0 0 NA 0
Other Current Liabilities NA 5 3 NA 10
Total Current Liabilities NA 45 57 NA 44
Mortgages NA 0 0 NA 0
Deferred Taxes/Income NA 65 0 NA 0
Convertible Debt NA 7 7 NA 20
Long-Term Debt NA 0 0 NA 0
Non-Current Capital Leases NA 0 0 NA 0
Other Non-Current Liabilities NA 239 NA 209
Minority Interest (Liabilities) NA 0 0 NA 0
Total Liabilities NA 363 303 NA 273
Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Preferred Stock NA 0 0 NA 0
Common Stock (Par) NA 2 2 NA 2
Capital Surplus NA 1,233 1,224 NA 1,203
Retained Earnings NA -1,117 -1,041 NA -860
Other Equity NA -1 -2 NA -5
Treasury Stock NA 2 2 NA 1
Total Shareholder's Equity NA 115 182 NA 339
Total Liabilities & Shareholder's Equity NA 478 485 NA 613
Total Common Equity 0 115 182 0 339
Shares Outstanding 191.90 191.50 191.60 190.40 190.00
Book Value Per Share 0.00 0.60 0.95 0.00 1.79